Form 4: Halozyme Director James Lang Receives Equity Grant

Director James Paul Lang received an annual grant of restricted stock units and stock options as part of Halozyme Therapeutics' director compensation program.

Summary

• Director James Paul Lang was granted 3,796 restricted stock units (RSUs) on May 5, 2026.
• Director Lang was granted 6,040 stock options with an exercise price of $65.87 on May 5, 2026.
• Both the RSUs and stock options are scheduled to vest on the earlier of May 5, 2027, or the date of the next annual meeting of stockholders.
• The RSUs are subject to a deferral election under the company's Directors Deferred Equity Compensation Plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial outlook.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

The equity grants are standard annual compensation for board members, indicating continued service and alignment with company performance.

Industry Context

StockSavvy.ai notes that annual equity grants to directors are standard corporate governance practice in the biotechnology sector to ensure board members maintain a long-term stake in company performance.

Comparison to Industry Standards

• The grant structure is consistent with standard director compensation packages for mid-cap biotechnology firms.
• Vesting periods of one year are typical for annual director equity awards.

Corporate Governance

Stakeholder Impact

• Minimal impact on shareholders as these are standard compensation grants.

Next Steps

• Vesting of equity awards on May 5, 2027, or the next annual meeting of stockholders.

Key Dates

Keywords

Halozyme, HALO, Form 4, Director Compensation, Insider Trading, Equity Grant